SCHEMBL13360504

SCHEMBL13360504

Cc1nc2n(c1C(C)C)CCCC2

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
TP53 P04637 2/20 0.40
LMNA P02545 1/20 0.40
PI4KA P42356 1/20 0.39
PI4K2B Q8TCG2 1/20 0.39
PI4K2A Q9BTU6 1/20 0.39
PI4KB Q9UBF8 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 2/20 0.38
THRB P10828 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MAPK1 P28482 2/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HDAC6 Q9UBN7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13328166 0.83 TP53 (0.39) POLBTP53LMNAPI4KAPI4K2B
SCHEMBL20086568 0.81 KDM4E (0.46) POLBTP53LMNAPI4KAPI4K2B
SCHEMBL13360488 0.78 POLB (0.48) POLBLMNAPI4KAPI4K2BPI4K2A
SCHEMBL22330447 0.78 MEN1 (0.41) POLBTP53LMNAPI4KAPI4K2B
SCHEMBL12414740 0.78 ALDH1A1 (0.46) POLBLMNASMN1; SMN2ALDH1A1HPGD
SCHEMBL22166764 0.77 KDM4E (0.41) POLBTP53LMNAPI4KAPI4K2B
SCHEMBL19006734 0.76 POLB (0.52) POLBLMNASMN1; SMN2ALDH1A1HPGD
SCHEMBL10239182 0.76 POLB (0.52) POLBLMNASMN1; SMN2ALDH1A1HPGD
SCHEMBL23890951 0.76 POLB (0.43) POLBTP53LMNAPI4KAPI4K2B
SCHEMBL19040334 0.76 KDM4E (0.51) POLBTP53LMNAPI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183237-A1 COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 VANDERBILT UNIVERSITY 2023-06-15 US disclosed
US-7718648-B2 Pyridobenzazepine compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-05-18 US disclosed
US-7572784-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-08-11 US disclosed
US-20080045501-A1 Pyridobenzazepine compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183237-A1 COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 CHRM5, CHRM1, CHRM2 POLB 3228/4885TP53 3849/4885LMNA 4600/4885
US-20080045501-A1 Pyridobenzazepine compounds and methods for inhibiting mitotic progression AURKB, AURKC, AURKA POLB 292/4885TP53 123/4885LMNA 829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.